Fri, Nov 28, 2014, 8:22 AM EST - U.S. Markets open in 1 hr 8 mins


% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • jetmanbash jetmanbash Feb 15, 2011 10:00 PM Flag

    MDVN update:

    Medivation and Astellas announce positive new, long-term follow-up data from phase 1-2 trial (18.63 +0.65)
    Medivation (MDVN) and Astellas Pharma Inc. today announced positive, new, long-term follow-up data from the Phase 1-2 trial of MDV3100 in patients with advanced prostate cancer. MDV3100 is a novel, triple-acting, oral androgen receptor antagonist. These new results showed that MDV3100 continues to show durable antitumor activity as evaluated by median times to prostate-specific antigen progression and radiographic progression. These findings confirm the initial Phase 1-2 results published in The Lancet, in which MDV3100 consistently demonstrated anti-tumor activity in both chemotherapy-naive and post-chemotherapy patients across endpoints, as evaluated by PSA levels, radiographic findings and circulating tumor cell counts.

2.11+0.02(+0.96%)Nov 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.